Biomea Fusion (BMEA) Income from Continuing Operations (2020 - 2026)
Biomea Fusion's (BMEA) quarterly Income from Continuing Operations came in at -$12.4 million in Q2 2026, up 40.64% year-over-year from -$8.9 million in Q2 2025, and down 0.83% quarter-over-quarter from -$12.3 million in Q1 2026.
Powered by 
Analysis
Biomea Fusion (BMEA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Biomea Fusion has disclosed Income from Continuing Operations across 7 years of filings, most recently posting -$12.4 million for Q2 2026.
- In Q2 2026, Income from Continuing Operations rose 40.64% year-over-year to -$12.4 million; the TTM figure through Jun 2026 stood at -$56.4 million (up 49.75% YoY), while the FY2025 annual figure was -$81.7 million, up 41.01% from the prior year.
- Income from Continuing Operations came in at -$12.4 million for Q2 2026 at Biomea Fusion, down from -$12.3 million in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of -$12.3 million in Q1 2026 to a low of -$39.1 million in Q1 2024.
- Average Income from Continuing Operations over 5 years is -$24.7 million, with a median of -$25.1 million recorded in 2022.
- Year-over-year, Income from Continuing Operations tumbled 179.67% in 2022 and jumped 57.82% in 2026.
- Over 5 years, Income from Continuing Operations stood at -$25.3 million in 2022, then slumped by 37.81% to -$34.9 million in 2023, then climbed by 16.0% to -$29.3 million in 2024, then soared by 47.97% to -$15.2 million in 2025, then rose by 18.35% to -$12.4 million in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were -$12.4 million in Q2 2026, -$12.3 million in Q1 2026, and -$15.2 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | -246.00 Mn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 3.32 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 2.16 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | -644.37 Mn |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 237.01 Mn |
| 10 | Biomea Fusion | 132.65 Mn | 132.65 Mn | - | -12.45 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -12.45 Mn |
| Mar 31, 2026 | -12.34 Mn |
| Dec 31, 2025 | -15.25 Mn |
| Sep 30, 2025 | -16.41 Mn |
| Jun 30, 2025 | -20.97 Mn |
| Mar 31, 2025 | -29.26 Mn |
| Dec 31, 2024 | -29.30 Mn |
| Sep 30, 2024 | -32.79 Mn |
| Jun 30, 2024 | -37.28 Mn |
| Mar 31, 2024 | -39.06 Mn |
| Dec 31, 2023 | -34.88 Mn |
| Sep 30, 2023 | -28.43 Mn |
| Jun 30, 2023 | -24.89 Mn |
| Mar 31, 2023 | -29.05 Mn |
| Dec 31, 2022 | -25.31 Mn |
| Sep 30, 2022 | -22.89 Mn |
| Jun 30, 2022 | -17.26 Mn |
| Mar 31, 2022 | -16.37 Mn |
| Dec 31, 2021 | -14.71 Mn |
| Sep 30, 2021 | -12.61 Mn |
API Access
Biomea Fusion Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=BMEA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "BMEA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=BMEA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();